FDA Releases Guidance on Resuming Normal Drug and Biologics Manufacturing Operations During COVID-19 (JSON)

lexblog.com/lib/MEGEN4ECview recordjson

{
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "FDA Releases Guidance on Resuming Normal Drug and Biologics Manufacturing Operations During COVID-19",
    "url": "https://www.lexblog.com/2020/09/17/fda-releases-guidance-on-resuming-normal-drug-and-biologics-manufacturing-operations-during-covid-19/",
    "identifier": {
        "@type": "PropertyValue",
        "name": "LexBlog Library record",
        "value": "LEX-WK-MEGEN4EC",
        "url": "https://www.lexblog.com/lib/MEGEN4EC/"
    },
    "datePublished": "2020-09-17T15:29:41-04:00",
    "dateModified": "2021-10-27T09:38:46-04:00",
    "author": {
        "@type": "Person",
        "name": "Thomas Cosgrove"
    },
    "sourceOrganization": {
        "@type": "Organization",
        "name": "Covington & Burling LLP"
    },
    "organizationScope": "at-publication",
    "isPartOf": "Global Policy Watch",
    "about": "Health Care and Life Sciences",
    "sourceUrl": "https://www.globalpolicywatch.com/?p=10352",
    "sourceStability": "may-move"
}